Stay updated on TAK-659 in AML Clinical Trial

Sign up to get notified when there's something new on the TAK-659 in AML Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the TAK-659 in AML Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T21:52:32.000Z thumbnail image
  4. Check
    3 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a potential update or revision in the context of a study related to the safety, tolerability, and efficacy of TAK-659 in adults with relapsed or refractory Acute Myelogenous Leukemia (AML).
    Difference
    0.1%
    Check dated 2024-06-06T14:42:59.000Z thumbnail image
  7. Check
    24 days ago
    Change Detected
    Summary
    The webpage has been updated to include detailed eligibility criteria for participants in the study, specifying that participants must be 18 years or older with a documented diagnosis of primary or secondary AML, among other criteria. Previously, no information was provided under Participation Criteria Collaborators.
    Difference
    48%
    Check dated 2024-05-22T21:29:52.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    0.7%
    Check dated 2024-04-30T22:33:07.000Z thumbnail image

Stay in the know with updates to TAK-659 in AML Clinical Trial

Enter your email address, and we'll notify you when there's something new on the TAK-659 in AML Clinical Trial page.